Resveratrol Modulates the Topoisomerase Inhibitory Potential of Doxorubicin in Human Colon Carcinoma Cells
Resveratrol (RSV) is currently being widely discussed as potentially useful for anticancer therapy in combination with classical chemotherapeutics, e.g., the topoisomerase II (TOP II) poison doxorubicin (DOX). However, there is still a lack of knowledge of possible interference at the target enzyme,...
Main Authors: | Anika Schroeter, Doris Marko |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/19/12/20054 |
Similar Items
-
Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line
by: Osman Abdel-Moneim M, et al.
Published: (2012-11-01) -
Newly Synthesized Imino-Derivatives Analogues of Resveratrol Exert Inhibitory Effects in Breast Tumor Cells
by: Domenico Iacopetta, et al.
Published: (2020-10-01) -
Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity
by: Zhang L, et al.
Published: (2019-07-01) -
Resveratrol overcomes TRAIL resistance in human colon cancer cells
by: Xiao-Bing Li, et al.
Published: (2015-07-01) -
The Ubiquitin-Conjugating Enzyme E2-EPF Is Overexpressed in Primary Breast Cancer and Modulates Sensitivity to Topoisomerase II Inhibition
by: Donato Tedesco, et al.
Published: (2007-07-01)